Hestia Insight Inc. Subsidiary Enters Into Corporate Advisory Agreement With Aquiva Medical Inc.

Published

LAS VEGAS, NV - (NewMediaWire) - March 21, 2024 - Hestia Insight Inc. (OTCQB: HSTA) ("Hestia Insight" and the "Company"), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, and providing marketing, management, business, and capital markets advisory services to its clients within the healthcare and biotech sectors, today announced that through its wholly owned subsidiary, Hestia Investments Inc., the Company entered into a corporate advisory agreement with Aquiva Medical Inc. ("Aquiva Medical"), an innovative healthcare company which operates within the dermatology medical technology sector.

Under the terms of the engagement, the Company provides strategic advisory services to Aquiva Medical to reinforce Aquiva's growth and expansion initiatives. Leveraging the Company's extensive expertise and network within the healthcare and biotech industries, Aquiva Medical hopes to hasten its U.S. market penetration and enhance its product development efforts.

In a recent milestone achievement, the Company advised Aquiva Medical in connection with Aquiva's successfully consummated merger transaction with BHPA, Inc., marking a significant step forward for Aquiva. The completion of this merger transaction underscores the Company's commitment to delivering strategic solutions and fostering impactful collaborations to its healthcare industry clients.

"We are thrilled about our engagement with Aquiva Medical and the early successes that we have achieved," said Edward Lee, CEO of Hestia Insight. Mr. Lee continued, "Aquiva's innovative approach to medical technology aligns perfectly with our mission to support healthcare companies that are at the forefront of innovation. We look forward to continuing to work closely with the Aquiva team to support their strategic objectives and drive innovation in the medical technology sector."

About Hestia Insight, Inc:

Hestia Insight Inc. ("Hestia Insight" and the "Company") is focused primarily on the healthcare and biotech sectors through the Company's two wholly owned operating subsidiaries, Hestia Investments Inc. ("Hestia Investments"), and HSTA Health Inc. ("HSTA Health"). Hestia Investments provides strategic consulting, medical supply sales and marketing support, and management, and capital markets advisory services for select micro, small and medium sized companies within the healthcare and biotech sectors. HSTA Health operates within the healthy food, beverage and wellness products industry and the smart vending machine industry. The Company is positioned to make strategic acquisitions of emerging growth companies with unique sciences and technologies. The Company intends to pursue the acquisition and development of healthcare related technologies in the healthcare and biotech sectors through acquisition, licensing, or joint ventures. The Company will also consider a third avenue of investing in certain technologies. The Company originally entered the healthcare sector to explore emerging healthcare technologies, especially growth companies that own and develop unique sciences and technologies.

For more information about Hestia Insight, please visit the Company's website: www.hestiainsight.com

Hestia Insight Investor Relations: investors.hestiainsight.com

Facebook: Hestia Insight Inc.

LinkedIn:  Hestia Insight Inc.

Twitter: @HestiaInsight

Hestia Insight is subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, in accordance with the Exchange Act, the Company files periodic reports, documents, and other information with the Securities and Exchange Commission (the "Commission") relating to our business, financial statements, and other matters. These filings are available to the public on the Commission's website at http://www.sec.gov.

Safe Harbor Provision

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created thereby. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the Company's future financial position, business strategy, plans and objectives, growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates, are forward-looking statements.  Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions.  Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements.  Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct.  Important factors that could cause actual results to differ materially from the Company's expectations include, but are not limited to, those factors set forth in the Company's Annual Report on Form 10-K for the year ended November 30, 2022 and its other filings and submissions with the Securities and Exchange Commission.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.  Except as required by law, the Company assumes no obligation to update or revise any forward-looking statements.

Investor Relations Contact: Ann Reyes Tel: 725.356.6077 Email: areyes@hestiainvestments.us

In This Story

HSTA